We enthusiastically read the letter regarding our article titled "Arterial stiffness evaluation in patients with irritable bowel syndrome: role of antihypertensive drugs and statins" published in Anatol J Cardiol 2014; 14: 525-30 ([@ref1]).

Increased arterial stiffness reflecting decreased arterial compliance is an important marker of vascular aging ([@ref2]). We demonstrated that carotid-femoral pulse wave velocity (PWV), the current gold standard measure of arterial stiffness did not differ between patients with irritable bowel disease and healthy control subjects ([@ref1]). Arterial stiffness is mainly associated with aging and hypertension ([@ref3]). As the authors kindly mentioned, antihypertensive drug groups tend to have different effects on arterial stiffness besides blood pressure-lowering effects. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and mineralocorticoid antagonists decrease PWV, whereas diuretics and β-blockers (except nebivolol) have neutral or negative influence ([@ref4]). The effect of statins on arterial stiffness is still controversial due to conflicting results ([@ref5], [@ref6]). Although, 23% of patient population and 37% of control group had hypertension in our study, there was no significant difference between the groups. Unfortunately

we did not record antihypertensive drug groups at inclusion; thus, we do not have the relevant data. We excluded patients on β-blocker treatment due to the impact on heart rate variability. Due to the facts that the percentage of hypertensive patients was not different statistically, exclusion of β-blocker treatment, and having only one patient on statin treatment within each group, we do not think these presumed drug associations would have influenced our results. We thank the authors for their scrutiny and valuable remarks.
